Living Cell Technologies Reports Interim Results Showing Sustained Benefit with DIABECELL® Implants for Insulin
Dependent Diabetes
February 11, 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)
reports positive interim results from the long term follow-up of insulin dependent diabetes patients in the Phase I/IIa
clinical trial of its lead product, DIABECELL®.
A total of seven patients have received DIABECELL® implants, five of whom have had two low dose (5,000 islet equivalents
(IEQs) per kg body weight) implants at least six months apart. There have been no remarkable adverse events attributed
to double implants. Two patients have received a single higher dose (10,000 IEQs/kg) with no safety concerns to date.
The results of 36 to 68 weeks follow-up from the first four patients showed that good blood glucose control was
maintained as reflected by a reduction in glycated hemoglogin (% HbA1c) levels from a mean of 8% pre-enrolment to 6.8%
at time of clinical review. The American Diabetes Association target for good blood glucose control is HbA1c below 7%
and the normal is less than 6.2%. This control was attained despite a reduction of 10% - 38% in the required daily
insulin dose.
It is too early to assess the second implant for the fifth patient. However, the patient’s HbA1c improved markedly from
9.8% before enrolment to 7.2% accompanied with a small reduction in the average daily insulin dose of 6%.
LCT Medical Director, Professor Bob Elliott said, “The patients clearly benefited from the implants administered at the
lowest dose. The second implant maintained this benefit. Remarkably none of the patients have had problems with
clinically relevant episodes of low blood glucose. Most people with diabetes cannot attain this degree of blood glucose
control shown by these patients without large swings of very low or high blood glucose levels that are often fatal.”
Two more patients have received the higher dose of DIABECELL®. Patient six declined further follow-up at 20 weeks after
the first implant when there was no change in glucose control or insulin dose. To improve consistency, LCT narrowed
product quality release specifications for all subsequent implants. Patient seven has been followed up for only four
weeks at which time HbA1c improved dramatically from 8.3% to 4.8% and daily insulin requirement dropped by 60%.
Professor Elliott further stated, “We can expect better outcomes with higher doses. The encapsulated cells offer not
only an alternative but a physiological replacement therapy to provide new hope and improved lifestyles for people with
diabetes.”
Dr Paul Tan, LCT Chief Executive Officer, said, “The next three patients in Russia are scheduled to receive the 10,000
IEQ/kg dose by April this year before testing the top dose of 15,000 IEQs/kg. Steps to initiate a pivotal trial and a
commercialization strategy in Russia have been taken.”
DIABECELL® is LCT’s encapsulated porcine insulin-producing cell product designed for the treatment of type 1 diabetes
without the use of immunosuppressive drugs.
-Ends-
About Living Cell Technologies: www.lctglobal.com
Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company
owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For
patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose
levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company
entered clinical trials for its diabetes product in 2007. For the treatment of Huntington’s disease and other
neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins
and neurotrophic factors to the brain. LCT’s technology enables healthy living cells to be injected into patients to
replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also
offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research
and other purposes.
LCT Disclaimer
This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the
use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”,
“forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could
provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual
results to be materially different from any future results, performance or achievements expressed or implied by such
statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other
health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such
product candidates will be approved by any health authorities for sale in any market or that they will reach any
particular level of sales. In particular, management’s expectations regarding the approval and commercialisation of the
product candidates could be affected by, among other things, unexpected clinical trial results, including additional
analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government
regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection;
competition in general; government, industry, and general public pricing pressures; and additional factors that involve
significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual
results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is
providing this information as of December 2008 and does not assume any obligation to update any forward-looking
statements contained in this document as a result of new information, future events or developments or otherwise.